US9074255 — Method of predicting a predisposition to QT prolongation
Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2030-12-17 · 5y remaining
What this patent protects
This patent protects a method for predicting a predisposition to QT prolongation and determining whether a compound, such as Fanapt, is capable of inducing QT prolongation.
USPTO Abstract
The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Drugs covered by this patent
- Fanapt (ILOPERIDONE) · Vanda Pharms Inc
- milsaperidone (Milsaperidone) · Vanda Pharmaceuticals
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1674 |
— | Fanapt |
U-4437 |
— | milsaperidone |
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-4437 |
— | milsaperidone |
U-4437 |
— | milsaperidone |
U-4437 |
— | milsaperidone |
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-4437 |
— | milsaperidone |
U-4437 |
— | milsaperidone |
U-4436 |
— | milsaperidone |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.